The endocytic receptor SORL1 has come to fruition both literally and figuratively. An interactive diagram of the 2,214 amino acid behemoth—filled with findings about hundreds of rare variants—is live for viewing on the Alzforum Mutations database. A handf
In the Finnish city of Kuopio, neurosurgeons collaborate with neurophysiologists and molecular and cellular biologists to make frontal cortex, dura, intraventricular CSF, skin, fat, and other tissue from hydrocephalus patients available for research purpo
Pumping Up Progranulin: Scientists Show New Efforts to Get it Done First Hit on Aggregated Tau: Antisense Oligonucleotide Lowers Tangles Tau Chimeras Do Make Fibrils—and a Chaperone Rips Them Apart Macrophages Blamed for Vascular Trouble in ApoE4 Carriers
Donanemab Data Anchors Upbeat AAIC Give BACE Inhibitors a Second Chance? CSF MTBR-tau-243 Tracks Tangles, Plummets in Response to Antibody Cohort LEADS Toward Better Understanding of Sporadic Early Onset AD Spying on α-Synuclein Inclusions: PET Tracers In
Cutting (or Slippery?) Edge: Lipids in Neurodegeneration Science Does the Brain Use Microglia to Maintain Its Myelin? Cracking the Cholesterol-AD Code: Metabolites and Cell Type Can Flipping a Lipid Switch Protect the Brain? The average human brain contai
To Recruit for Diverse Alzheimer Trials, Go to the People From St. Louis to Boston, Scientists Grapple with Ethnoracial Divide in AD Biomarkers Treat Before ‘Aβ Bothers Tau,’ Scientists Say at CTAD Moving Forward: RNA-Targeted Attempts at Taking Down Tau,
Second Holloway Summit Showcases Intense Search for FTD Biomarkers At Holloway Summit, FTD Imaging Shows New Vista To enable clinical trials in frontotemporal dementia, scientists need biomarkers that distinguish its several underlying pathologies. At a r
Fast Plaque Clearance with Little ARIA? So Teases Trontinemab at AD/PD 2024 TauRx Parses Subgroups to Make the Case for Methylene Blue Derivative, Again Therapeutic Contenders Target Hard-to-Reach Pockets of Tau Mouse Models and Markers for Cerebral Amylo
Inclusions in tau seed sensor cells are made of amyloid fibrils, say scientists at AD/PD 2023. In those cells, and in human neurons, a dis-aggregase shreds them.
Biogen/IONIS’s tau ASO BIIB080 dropped participants’ tau PET signal below baseline in six months of treatment, according to data from a Phase 1 study presented at AD/PD.
At AD/PD, scientists showed 3- and 4-year amyloid immunotherapy data hinting at sustained cognitive benefits. The number of remaining participants is tiny.